Musculoskeletal disorders are a significant burden on the global economy and public health. Hydrogels have significant potential for enhancing the repair of damaged and injured musculoskeletal tissues as cell or drug delivery systems. Hydrogels have unique physicochemical properties which make them promising platforms for controlling cell functions. Gelatin methacryloyl (GelMA) hydrogel in particular has been extensively investigated as a promising biomaterial due to its tuneable and beneficial properties and has been widely used in different biomedical applications. In this review, a detailed overview of GelMA synthesis, hydrogel design and applications in regenerative medicine is provided. After summarising recent progress in hydrogels more broadly, we highlight recent advances of GelMA hydrogels in the emerging fields of musculoskeletal drug delivery, involving therapeutic drugs (e.g., growth factors, antimicrobial molecules, immunomodulatory drugs and cells), delivery approaches (e.g., single-, dual-release system), and material design (e.g., addition of organic or inorganic materials, 3D printing). The review concludes with future perspectives and associated challenges for developing local drug delivery for musculoskeletal applications.
Bibliographical noteFunding Information:
Y.-H.K., R.O.C.O. and J.I.D. gratefully acknowledge support from the MRC-AMED Regenerative Medicine and Stem Cell Research Initiative (MR/V00543X/1) and the EPSRC (EP/S017054/1). R.O.C.O. acknowledges financial support from the Biotechnology and Biological Sciences Research Council (BB/P017711/1) and the UK Regenerative Medicine Platform “Acellular/Smart Materials—3D Architecture” (MR/R015651/1). I.M. and C.A. acknowledge the financial support from the Assistant Secretary of Defence for Health Affairs through the Peer Reviewed Orthopaedic Research Program (PRORP) under Applied Research Award No. W81XWH-20-1-0563. Army Medical Research Acquisition Activity, 839 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defence. I.M. also acknowledges the financial support from the University of Minnesota’s Office of Academic Clinical Affairs Faculty Research Development Grant.
This research was funded by MRC-AMED Regenerative Meicine and Stem ell Research Initiative (MR/V00543X/1), EPSRC (EP/S017054/1), Biotechnology and Biological Sciences Research Council (BB/P017711/1), UK Regenerative Medicine Platform “Acellular/Smart Materials—3D Architecture” (MR/R015651/1), Assistant Secretary of Defence for Health Affairs through the Peer Reviewed Orthopaedic Research Program (PRORP) under Applied Research Award (No W81XWH-20-1-0563), Army Medical Research Acquisition Activity, 839 Chandler Street, Fort Detrick MD 21702-5014, and the University of Minnesota’s Office of Academic Clinical Affairs Faculty Research Development Grant.
© 2022 by the authors.
- drug delivery
- musculoskeletal tissue
PubMed: MeSH publication types
- Journal Article